- Home
- HBNC vs SGP Comparison
HBNC vs SGP Comparison
Compare HBNC & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HBNC | SGP |
|---|---|---|
| Founded | 1873 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 883.5M | 932.9M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | HBNC | SGP |
|---|---|---|
| Price | $15.85 | $26.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $20.33 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 356.9K | 91.2K |
| Earning Date | 03-30-2026 | 01-01-0001 |
| Dividend Yield | ★ 4.02% | N/A |
| EPS Growth | ★ 25.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $51.78 | N/A |
| Revenue Next Year | $10.63 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.70 | $24.71 |
| 52 Week High | $19.07 | $30.56 |
Technical Indicators
Market Signals| Indicator | HBNC | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 30.85 | 48.43 |
| Support Level | $15.74 | $25.38 |
| Resistance Level | $16.66 | $29.71 |
| Average True Range (ATR) | 0.49 | 1.61 |
| MACD | -0.14 | -0.21 |
| Stochastic Oscillator | 9.80 | 25.65 |
Price Performance
Historical ComparisonAbout HBNC Horizon Bancorp Inc.
Horizon Bancorp (IN) is a United States-based holding company providing banking services. It is engaged in providing commercial and retail banking services, corporate and individual trust and agency services, and other services incident to banking. The company also provides commercial loans, real estate loans, mortgage warehouse loans, consumer loans, and other credit facilities. The company has one principal business segment, commercial banking.
About SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.